Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZ6T9E)

• DTT Name: Somatostatin receptor type 2 (SSTR2) DTT Info
• Gene Name: SSTR2

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Copper dotatate Cu-64	DM26KR1	Diagnostic imaging	N.A.	Approved	[1]
Ga-68-DOTATOC	DMZ0P95	Diagnostic imaging	N.A.	Approved	[2]
Lanreotide acetate	DMG6ZU4	Acromegaly	5A60.0	Approved	[3]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[4]
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[5]

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
Paltusotine	DM97IN2	Acromegaly	5A60.0	Phase 3	[7]
TBR-760	DMM5BVG	Pituitary adenoma	2F37.0	Phase 2	[8]
PEN-221	DMMAUOK	Neuroendocrine cancer	2B72.1	Phase 1/2	[9]
Re-188-P-2045	DM614BA	Lung cancer	2C25.0	Phase 1/2	[10]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[11]

29 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
98mTc-CIM-ANT	DMJ1VAE	Neuroendocrine cancer	2B72.1	Investigative	[5]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[5]
Ala11-SRIF-14-amide	DMZH4NQ	Discovery agent	N.A.	Investigative	[12]
Ala6-SRIF-14-amide	DM9RQ7E	Discovery agent	N.A.	Investigative	[12]
Ala7-SRIF-14-amide	DMWF8GN	Discovery agent	N.A.	Investigative	[12]
CGP 23996	DMTECXA	Discovery agent	N.A.	Investigative	[13]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[14]
D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2	DM0YQHM	Discovery agent	N.A.	Investigative	[15]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,4,13-[D-Trp8]SRIF	DMR6Z2N	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF	DMJI6BK	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,4,5,13-[D-Trp8]-SRIF	DMYZXEO	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF	DM6HZ8D	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,4,5-[D-Trp8]SRIF	DMEN4G8	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[16]
Des-AA5-[D-Trp8]SRIF	DMO3CFV	Discovery agent	N.A.	Investigative	[16]
H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH	DMCQH23	Discovery agent	N.A.	Investigative	[17]
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2	DM1EGC3	Discovery agent	N.A.	Investigative	[15]
H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2	DML8S7J	Discovery agent	N.A.	Investigative	[17]
H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2	DMLCIZ8	Discovery agent	N.A.	Investigative	[17]
L-054,522	DMQR6ZX	Discovery agent	N.A.	Investigative	[18]
L-054852	DMXB7G5	Acromegaly	5A60.0	Investigative	[3]
L-779,976	DMMUAW5	Discovery agent	N.A.	Investigative	[19]
Pyz11-D-Trp8-SRIF	DMFUYR1	Discovery agent	N.A.	Investigative	[12]
Pyz6-D-Trp8-SRIF	DMDB3Q8	Discovery agent	N.A.	Investigative	[12]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[15]
SRIF-14	DMDY1M7	Discovery agent	N.A.	Investigative	[13]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[20]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
• [4] Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
• [6] Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
• [7] Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
• [8] TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
• [11] Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
• [12] Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30.
• [13] [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20.
• [14] An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
• [15] Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
• [16] Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
• [17] Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96.
• [18] Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41.
• [19] Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40.
• [20] Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.